Comparison of nine platelet function tests used to determine responses to different aspirin dosages in people with type 2 Diabetes

Harrison, Paul; bethel, angelyn; Kennedy, Irene; Dinsdale, Robert; Coleman, Ruth; Holman, Rury

DOI:

[10.1080/09537104.2018.1478402](https://doi.org/10.1080/09537104.2018.1478402)

License:

None: All rights reserved

Document Version

Peer reviewed version

Citation for published version (Harvard):

Harrison, P, bethel, A, Kennedy, I, Dinsdale, R, Coleman, R & Holman, R 2018, 'Comparison of nine platelet function tests used to determine responses to different aspirin dosages in people with type 2 Diabetes: platelet function testing in type 2 Diabetes', *Platelets*. <https://doi.org/10.1080/09537104.2018.1478402>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

Checked for eligibility: 21/05/2018

This is an Accepted Manuscript of an article published by Taylor & Francis in *Platelets* on 9th July 2018, available online: <http://www.tandfonline.com/10.1080/09537104.2018.1478402>

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Comparison of Nine Platelet Function Tests Used to Determine Responses to Different Aspirin Dosages in People with Type 2 Diabetes

Paul Harrison¹, M. Angelyn Bethel², Irene Kennedy^{2,3}, Robert Dinsdale¹, Ruth Coleman^{2,3}, Rory R. Holman^{2,3}

¹Institute of Inflammation and Ageing, University of Birmingham Medical School, Birmingham, UK; ²Diabetes Trials Unit, University of Oxford, Oxford, UK; ³Oxford National Institute for Health Research Biomedical Research Centre, Churchill Hospital, Oxford, U.K.

Correspondence:

Dr. Paul Harrison
Institute of Inflammation and Ageing
University of Birmingham Medical School
Birmingham
B15 2TT
United Kingdom

Phone: +44 (0)121 371 3251

Email: p.harrison.1@bham.ac.uk

Short Running Title :- Platelet Function Testing in Type 2 Diabetes

Key Words :- Platelet Function, Aspirin, Type 2 Diabetes

Abstract

The antiplatelet efficacy of aspirin (ASA) is reduced in type 2 diabetes (T2D). As the best ex-vivo method of measuring ASA efficacy remains uncertain, we compared nine platelet function tests to assess responsiveness to 3 ASA dosing regimens in 24 T2D patients randomized in a 3-treatment crossover design to ASA 100 mg/day, 200 mg/day or 100 mg twice daily for 2-week treatment periods. Platelet function tests compared were: Light transmission aggregometry (LTA-0.5mg/ml of arachidonic acid (AA) and 10 μ M ADP); Multiplate whole blood aggregometry (WBA-0.5mM AA and 6.5 μ M ADP); PFA-100TM-CADP and CEPI; VerifyNowTM-ASA; Urinary 11-dehydro-thromboxane B2 (TxB₂) and Serum TxB₂. All cyclo-oxygenase (COX-1) dependent tests and some COX-1 independent tests (PFA-CEPI, LTA-ADP) demonstrated significant reductions in platelet reactivity with all ASA doses. Two COX-1 independent tests (WBA-ADP and PFA-CADP) showed no overall reduction in platelet reactivity. Overall classifications for detecting all ASA doses, compared to baseline, were: Very good-LTA-AA ($k=0.95$) and VerifyNowTM-ASA ($k=0.85$); Good-Serum TxB₂ ($k=0.79$); Moderate-LTA-ADP ($k=0.59$), PFA-100TM-CEPI ($k=0.56$), Urinary TxB₂ ($k=0.55$), WBA-AA ($k=0.47$); Poor-PFA-100TM-CADP ($k=-0.02$) and WBA-ADP ($k=-0.07$). No significant kappa statistic differences were seen for each test for each ASA dose. Correlations for each test with serum TxB₂ measurements were: Very good - VerifyNowTM-ASA ($k=0.81$, $R^2=0.56$), LTA-AA ($k=0.85$, $R^2=0.65$); Good-PFA-100TM-CEPI ($k=0.62$, $R^2=0.30$); Moderate-Urinary TxB₂ ($k=0.57$, $R^2=0.51$), LTA-ADP ($k=0.47$, $R^2=0.56$); Fair-WBA-AA ($k=0.31$, $R^2=0.31$) and Poor-PFA-100TM-CADP ($k=0.04$, $R^2=0.003$), WBA-ADP ($k=-0.04$, $R^2=0.0005$). The platelet function tests we assessed were not equally effective in measuring the antiplatelet effect of ASA, and correlated poorly amongst themselves but COX-1 dependent tests performed better than non-COX-1 dependent tests.

Introduction

Reduced efficacy of aspirin (ASA) to inhibit platelet aggregation is observed frequently in type 2 diabetes (T2D), compared with the general population, and has been referred to as “ASA resistance” or hypo-responsiveness [1-3]. Failure to respond to ASA therapy is normally a result of a combination of factors including genetic polymorphisms, drug interactions and poor compliance [4, 5]. Despite this, current guidelines do not recommend laboratory testing for monitoring and personalising ASA therapy [6]. T2D is a pro-thrombotic state characterized by increased platelet reactivity and turnover, increased hepatic synthesis of fibrinogen and plasminogen activator inhibitor (PAI-1) and quantitative changes in the glycation and oxidation of clotting factors [1, 7, 8]. Accordingly, it is possible that higher or more frequent doses of ASA might be required to potentially overcome metabolic barriers in T2D, particularly in conditions where platelet turnover is increased [9]. Once-daily low dose ASA dosing may be, therefore, insufficient when platelet turnover is increased as irreversibly inhibited platelets are removed more rapidly from the circulation and replaced by new platelets not yet exposed to ASA [9-11]. Enteric coatings of ASA have also been shown to be an important variable for contributing to reduced bioavailability and poor responsiveness to ASA in T2D [12]. Twice daily dosing has also been advocated for treating patients with essential thrombocythemia as well as T2D where there is evidence of increased platelet turnover [13, 14].

Our recent study demonstrated that ASA 100 mg given twice daily was more effective in reducing platelet reactivity than 100 mg given once daily in T2D, despite showing that there was no evidence of increased platelet turnover in these patients [15]. The study primary objective was to compare changes from baseline in platelet reactivity with each of three ASA regimens, as measured by the VerifyNow™-ASA point-of-care test (POC) (Accumetrics, CA, USA)[16, 17]. Secondary objectives were to further assess changes in platelet function using a variety of both specialised and point-of-care COX-1 dependent/independent platelet function tests. Many tests are now available for measuring inhibition of platelet function but they are becoming increasingly diverse and simpler to perform [18]. Although light transmission aggregometry (LTA) is still regarded as the gold standard despite being invented in the 1960's, poor standardization and its restriction to specialised laboratories means that the test is limited for potential clinical utility [18]. Measurement of thromboxane and its

metabolites within serum and urine are important for specifically measuring the biochemical consequences of ASA inhibition of platelet COX-1 activity but again are both restricted to specialised laboratories. In the last 20 years a number of simpler semi and full point-of-care tests have been developed (e.g. PFA-100™, Multiplate and VerifyNow™) but it is still unclear whether these tests are actually useful for monitoring ASA in this context and how they may perform against LTA and Thromboxane measurements [18-20]. As we previously demonstrated that there were clear differences in the ability of some of these tests to detect differences between the 3 ASA dose regimens [15], the aim of this additional study was therefore to not only compare and contrast but examine in detail the performance characteristics of all these tests in each of the three ASA regimens used in the trial.

Materials and Methods

This investigator-led, single-centre, randomized, prospective, double-blind study received ethical approval from the South East London Research Ethics Committee 3 [15]. It complied with The World Medical Association Declaration of Helsinki (1964) and its amendments and clarifications, the European Union Clinical Trials Directive (2001/20/EC), and International Conference on Harmonisation Harmonized Tripartite Guideline for Good Clinical Practice (CPMP/ICH/135/95). All participants provided written informed consent. The authors are solely responsible for the design, conduct, and analysis of this study, the drafting and editing of the manuscript, and its final contents.

Participants

Twenty-four patients with T2D were recruited from local primary care clinics and from the Oxford Centre for Diabetes, Endocrinology, and Metabolism research recruitment register. Eligible participants were required to be at least 18 years of age, have no prior history of cardiovascular disease, be on stable diabetes therapy with diet or oral anti-hyperglycemic agents for at least 3 months, with HbA1c < 10% (86 mmol/mol) and triglycerides ≤2 mmol/L. Patients with the following conditions were excluded: pregnant or lactating; peptic ulcer disease or other gastro-intestinal disorder; blood pressure >150/100 mmHg; bleeding disorder; evidence of severe hepatic disease or ALT>3-times the upper limit of normal; severe

renal disease or eGFR $<40\text{ml/min/1.73m}^2$; currently taking or with a contraindication to treatment with aspirin.

Study design

In this 3-treatment, crossover study, participants were randomized to one of six possible treatment sequences during which they received the identical formulation of ASA (acetylsalicylic acid, Bayer Pharma AG, Germany) or matching placebo as two tablets twice a day according to 3 different regimens with active therapy ; 100 mg once-daily, 200 mg once-daily or 100 mg twice-daily. Each 2-week treatment period was followed by a 2-week washout [15]. ASA doses were chosen to approximate doses used in clinical practice and to facilitate the use of a double-blinded placebo control.

Blood Sampling

Fasting venous blood and urine samples were taken at baseline, and then on completion of each treatment period. All samples were taken between 8 am and noon and 12 or 24 hours after the ingestion of the last ASA dose (depending upon the dosage regime) to minimize the immediate impact of ASA administration and circadian effects on platelet function. Samples were transported to the local platelet laboratory by hand in upright tubes in a rack kept at room temperature, with platelet function testing performed > 30 minutes but within 4 hours of collection in keeping with British Committee for Standards in Haematology guidelines for platelet function testing. All samples were coded and blinded for ASA dosages. Blood samples for platelet function (LTA, PFA-100TM and WBA) were anticoagulated with 1/10 volume of 3.2% trisodium citrate in vacutainers (Becton Dickinson, Oxford UK). As recommended the 2 mL Greiner Bio-One partial-fill vacuette tube with 1/10 volume of 3.2% sodium citrate was used for blood samples to be tested on the VerifyNowTM-ASA. Serum samples were clotted at 37°C with a standardised incubation of 30 minutes before centrifugation at 2000 g for 20 minutes and the serum stored at -70°C until analysis. Stabilized urine samples were collected into universal tubes (25 ml) and stored in aliquots at 70°C until analysis. EDTA vacutainers were used for blood counting.

Platelet Function Testing

The VerifyNowTM-ASA (Accumetrics, CA, USA) test was selected as being the most convenient method for assessing the impact of ASA on platelet reactivity in this trial. The primary objective was therefore to compare changes from baseline in platelet reactivity with each of three ASA regimens [15]. The VerifyNowTM-ASA Point-of Care test Cartridges were stored at 4°C and warmed up to room temperature before analysis. The same batch of cartridges was used for the entire trial. Internal quality control of the instrument was performed on each day of testing and test cartridges were then loaded into the instrument immediately followed by insertion of the mixed special citrated whole blood sample onto the needle within the cartridge to initiate the test. The instrument then withdraws the blood under vacuum into the various reaction channels of the cartridge where automated LTA is then performed using arachidonic acid as the agonist. After the test has finished the results were displayed and printed. The results of this test, which is based on turbidimetric optical detection of platelet aggregation in whole blood, are expressed in ASA reactive units (ARUs), with a lower limit of normal (LLN) >550 ARU. Secondary objectives were to further assess changes in platelet function using a variety of COX-1 dependent and COX-1 independent platelet function tests. Light transmission aggregometry (LTA) was measured with a PAP-4 light transmission aggregometer (Biodata corporation) with 0.5 mg/mL arachidonic acid (AA) and 10 µM adenosine diphosphate (ADP) as agonists with unadjusted Platelet Rich Plasma (PRP) counts in line with recent guidelines. PRP was prepared by centrifugation of citrated whole blood by centrifugation at 200 g for 10 minutes and stored at room temperature in capped tubes. Platelet Poor Plasma (PPP) was prepared by centrifugation at 2000 g for 20 minutes. 270 µl of PRP and PPP was pipetted into PAP-4 aggregometry tubes and a magnetic stir bar added to the PRP tube and the tubes incubated at 37°C for 5 minutes before testing. In each channel, 100% maximal aggregation was set with PPP and then a 0% baseline established with PRP for at least 2 minutes before addition of 30 µl of stock agonists. The same source and batch of each agonist were used for the entire study and stored frozen at -70°C. Arachidonic acid was stored frozen at 5 mg/ml in distilled water in glass vials. Before testing agonists were thawed and then kept on ice. Results were reported as maximal platelet aggregation after 10 minutes with LLN ≥20% for AA and ≥70% for ADP. Multiple electrode whole blood aggregometry (WBA) was performed using a 5-channel MultiplateTM aggregometer (Roche Diagnostics, Munich, Germany) with an integrated computer and guided automatic pipetting. Citrated whole blood samples were mixed gently before pipetting into disposable ready to use test cells containing

two independent sensor units consisting of two silver coated highly conductive copper electrodes and a stir-bar. In each test cuvette, mixed whole blood was immediately diluted 1:1 vol/vol with 0.9% saline solution at 37°C for 3 minutes before addition of 30 µl of each agonist. Final concentration of agonists were 0.5 mM AA and 6.5 µM ADP as provided by the manufacturer. Results are expressed as area under the curve (AUC) with LLN >71 for AA and >57 for ADP as provided by the manufacturer. The platelet function analyzer (PFA-100™, Siemens Diagnostics, IL, USA) used either collagen and epinephrine (CEPI) or collagen and adenosine diphosphate (CADP) cartridges to measure platelet thrombus formation under high shear. Cartridges were stored at 4°C and warmed up to room temperature before testing commenced and the same batch used for the entire trial. A daily quality control instrument check was also performed on days of testing. 0.8 ml of citrated whole blood was pipetted into the sample reservoir each cartridge to initiate the test. Results were reported as closure times (CT) in seconds with upper limit of the normal range >164 seconds for CEPI and >112 seconds for CADP. Maximal CTs were recorded as >300 seconds. Pharmacologic effects of ASA were assessed by measuring serum thromboxane B₂ (TxB₂) and urinary 11-dehydrothromboxane B₂ (dTxB₂). Serum TxB₂ was assayed by ELISA (R&D systems, Abingdon, UK) according to the manufacturer's instructions with LLN 10 ng/mL. Urinary dTxB₂ was measured using ELISA (AspirinWorks Test kit, Corgenix, Peterborough, UK) according to the manufacturer's instructions with LLN ≥1500 pg/mg urinary creatinine. For both assays all samples were diluted appropriately so that the optical densities were within the standard curve. Creatinine levels were measured in the pathology department at the John Radcliffe Hospital in Oxford.

Statistical Analysis

Sample size estimates based on previous VerifyNow™-ASA Point-of Care studies suggested that 17 patients would be required to detect a clinically-significant 27% effect size between any two ASA regimens, with 90% power at the 5% significance level. A total of 24 patients were recruited to ensure balanced allocation to the 6 possible treatment sequences, and to allow for potential dropouts. The results of all platelet function tests were compared at baseline and after each ASA regimen using kappa statistics. Each platelet function test was also compared with Serum TxB₂ (as a measure of the direct pharmacological action of ASA)

and Arachidonic Acid stimulated LTA (the perceived gold standard of platelet function testing) by kappa statistics and Spearman correlations.

Results

Participant Characteristics

Participant baseline characteristics are summarized in the primary outcome paper [15]. Briefly, participants were mean ($\pm 1SD$) age 51 ± 7 years, BMI 31.4 ± 7.2 kg/m² with a median duration of diabetes of 2 years. Nineteen participants were treated with metformin, 6 with a sulfonylurea and 2 with a thiazolidinedione. None were treated with other glucose-lowering therapies at any time during the study.

For the primary objective, data from two of the 72 treatment periods were excluded because study medication was not taken within 24 hours of assessment (one period of ASA 200 mg once-daily and one of ASA 100 mg twice-daily). The same 70 treatment periods were used for the secondary objectives, except for urinary dehydro-thromboxane B₂ analyses which were limited to the 67 treatment periods with the requisite data available.

Effect of ASA dose on COX-1 dependent tests

Figure 1 shows the distribution of results for each COX-1 dependent platelet function test at baseline and for each of the three ASA doses. VerifyNowTM-ASA platelet reactivity decreased significantly from baseline 650 ± 19 to 448 ± 68 with ASA 100 mg once-daily, 430 ± 65 with 200 mg once-daily and 416 ± 39 with 100mg twice-daily (p all < 0.0001). Modelled platelet reactivity was reduced to a greater extent with ASA 100 mg twice-daily versus 100 mg once-daily ($p=0.043$), but not versus 200 mg once-daily ($p=0.44$). ASA 200 mg once-daily did not differ from 100 mg once-daily ($p=0.20$). Interestingly there were only 2 out of 24 patients who gave full aggregation responses by VerifyNowTM-ASA with ASA 100 mg once-daily. This was also mirrored in the other tests including serum TxB₂ and urinary dTxB₂, PFA-100TM-CEPI and CADP but only 1 of the 2 still gave full aggregation with LTA-AA. Only 1 of these patients then gave a full response by VerifyNowTM-ASA with ASA 200 mg once daily but this was still consistent with serum TxB₂ and urinary dTxB₂, PFA-100TM-CEPI and CADP and LTA-AA. However, at ASA

100 mg twice daily all platelet function was inhibited in this individual except PFA-100TM-CEPI. This could have been caused by true “ASA resistance” and/or poor compliance that was eventually overcome by ASA 100 mg twice daily. A failure to comply with the ASA dosage regime was felt unlikely in this individual as pill counts and interviews were performed and that both the serum TxB₂ and urinary dTxB₂ levels were still significantly reduced from baseline levels but above the accepted cut off values for these assays. The other COX-1 dependent platelet function tests also showed significant decreases from baseline with all three ASA regimens ($p < 0.0001$). The generalized mixed model demonstrated that, compared to ASA 100 mg once-daily, ASA 100 mg twice-daily produced statistically significant reductions from baseline for all COX-1 dependent platelet function tests except LTA-AA. There was no statistical difference for COX-1 dependent tests between ASA 100 mg twice-daily and 200 mg once-daily. Furthermore, ASA 200 mg once daily more effectively reduced WBA-AA than 100 mg once-daily. Pharmacologic suppression of COX-1 activity compared to baseline was demonstrated at all ASA doses, as measured by decreased serum TxB₂ and urinary dTxB₂. A greater pharmacologic effect was observed with ASA 100 mg twice-daily compared to 100mg once-daily for urinary dTxB₂ ($p=0.048$) with a similar but non-significant trend for serum TxB₂.

Effect of ASA dose on non-COX-1 dependent tests

Figure 2 shows the distribution of results for each non-COX-1 dependent platelet function test at baseline and for each of the 3 ASA doses. Neither the PFA-100TM-CADP nor the WBA-ADP platelet function tests showed any significant reduction from baseline. ASA 100 mg twice-daily produced a greater effect on PFA-100TM-CEPI compared to 100 mg once-daily, but no such difference was observed with any other COX-1 independent test. There were no statistical differences for any COX-1 independent test between ASA 100 mg twice-daily and 200 mg once-daily.

Kappa Statistics

The overall kappa statistic classifications for baseline and all ASA dosages are shown in Table 1. No differences were observed with each test for each ASA dose.

Comparison with serum TxB₂

Figure 3 shows the scatter plots comparing each test with serum TxB₂ and shows the results for baseline and the 3 ASA dosage regimens. In general COX-1 dependent tests not only correlated better with serum TxB₂ than non-COX-1 dependent tests but gave better agreement.

Comparison with LTA-AA

Figure 4 shows the scatter plots comparing each test with LTA-AA and shows the results for baseline and the 3 ASA dosage regimens.

Discussion

Full details of the primary outcomes of the trial have been previously published, showing that 100 mg of ASA twice-daily in T2D reduced platelet reactivity more effectively than 100 mg once-daily, and numerically more than 200 mg once-daily [15]. This regimen was also the most effective based on the pharmacologic effect on serum and urinary TxB₂ levels, and for reducing platelet reactivity as measured by a number of platelet function tests, *i.e.* VerifyNowTM-ASA, WBA-AA and PFA-100TM-CEPI.

We have now compared the secondary outcome results by comparing the performance of all nine different platelet function assays used in this trial. As this trial was a small study in 24 patients it was not feasible to measure the clinical efficacy of each test for prevention of ischaemic events. However, It is clear that the different platelet function tests evaluated are not equally effective in measuring the antiplatelet effects of ASA in T2D. The COX-1 dependent tests (e.g. VerifyNowTM-ASA, LTA-AA and Serum TxB₂) in general not only performed much better in correctly identifying patients at baseline and on 3 different dosages of ASA (Figures 1 and 2) but also correlated better with serum TxB₂ levels and LTA-AA than non-COX 1 dependent tests (Figure 3). The incidence of ASA non-responders is therefore also much lower in COX-1 dependent tests at all doses of ASA. As all the assays used in this study measure different aspects of platelet function, the observed differences between the tests is unsurprising and confirms the results from previous studies comparing the results from these

tests in different types of patients receiving either ASA and/or P₂Y₁₂ inhibitors [21-24]. One of the major limitations of these tests is the use of cut-off values that have not been clinically validated and are either arbitrarily defined or established upon the responsiveness of normal individuals to ASA either if given in vivo or added to blood in vitro. The VerifyNow™-ASA test is the only true FDA approved POC assay used in this trial and has been shown in some studies to relate to clinical outcomes [25, 26]. The advantage of this whole blood cartridge-based test is that it can be potentially used by non-platelet specialists away from the laboratory and does not require any pipetting of the blood sample during testing. As this test is now widely used, it is therefore important that the test is also validated against a range of tests as previous studies have shown variable results. In this study the overall agreement with either LTA-AA (k = 0.95, Figure 4) (the perceived gold standard) or Serum TxB₂ levels (k = 0.85, Figure 3) (a measure of pharmacological inhibition) was very good and it performed better than in other studies directly comparing these tests in different populations of patients [23, 24]. Given that the test now uses arachidonic acid, one would expect a reasonable correlation with other tests using the same agonists. The test was also performed in a specialist laboratory (and not as a POC test) at exactly the same time as other platelet function tests within locally taken fresh samples within a defined window of time and within a controlled clinical trial in a relatively homogeneous group of T2D patients. Some of the older comparisons of VerifyNow™-ASA were also performed using cartridges that utilised a different agonist (e.g. propyl gallate and not arachidonic acid) which may explain some of the previous reported differences [17, 27].

Of the other assays used in this study LTA-AA is still considered as the historical gold standard of platelet function testing [18]. As the assay also used arachidonic acid to drive platelet activation and aggregation it should be reasonably specific for measuring COX-1 activity as TxA₂ generation is a critical for amplification of initial platelet activation to drive secondary aggregation. Indeed, as one might expect LTA-AA not only agreed very well with serum TxB₂ measurements (k = 0.83) but also VerifyNow™-ASA (k = 0.95), the latter assay using the same agonist. However, despite its good performance in this study its major disadvantage is that it is a specialist test and therefore can only be used by operators with expertise in performing this test. We also used ADP as an agonist as this has been widely used to measure ASA responses by LTA. As ADP stimulation is not specific for measuring COX-1 activity, low

concentrations of ADP ($< 10 \mu\text{M}$) still require COX-1 activity for full aggregation responses to occur. Higher concentrations of ADP ($> 10 \mu\text{M}$) are thought to be COX-1 independent so there is a debate over which concentrations of ADP are optimal for measuring ASA inhibition. Indeed in this study we chose an intermediate concentration of $10 \mu\text{M}$ ADP, as we have previously shown that ASA does inhibit secondary aggregation responses at this dose. It is probably not surprising that the overall performance was therefore moderate and with hindsight a lower concentration of $5 \mu\text{M}$ ADP could have been used instead, which has been shown to perform better than higher concentrations for monitoring ASA [24]. As LTA is performed in PRP we also wanted to compare results with whole blood aggregometry as this is not only used in the VerifyNowTM-ASA test but is argued to be more physiological and does not require centrifugation steps to prepare samples for testing. WBA using the Multiplate system has also become an established test for monitoring P_2Y_{12} antagonists as this instrument uses disposable cuvettes and because of its ease of use has also been used as a POC test within intensive care settings [28]. In this study WBA using either AA or ADP as the agonists gave either a moderate or poor performance respectively. Although whole blood is probably more physiological the results are probably not surprising given that alternative mechanisms of platelet activation are highly likely to occur within whole blood which could potentially bypass any ASA inhibition of COX-1 activity. The PFA-100TM also utilises whole blood but does not measure platelet function in the same way as classical or whole blood aggregometry [19]. Instead, the instrument measures high shear dependent platelet thrombus formation in real time which could be argued to be more physiological and is rapid and simple to use. Again the test is FDA approved for measuring platelet dysfunction and has been widely used to detect ASA responses within the CEPI cartridge but not the CADP cartridge which has been previously shown to be relatively insensitive to ASA [29]. Indeed in this study the CEPI cartridge performed either moderately or good in comparison with ASA dose and serum TxB_2 measurements respectively. In contrast, the CADP cartridge performed poorly as expected. Previous studies have shown that the PFA-100TM CEPI cartridge can sometimes be totally insensitive to ASA and be effectively by-passed in conditions where there is platelet hyper-reactivity and/or high von Willebrand factor (VWF) levels, which are known to be elevated in patients with coronary artery disease or T2D [30]. This can even occur when COX-1 activity is effectively blocked by ASA as assessed by TxA_2 measurements in the

same samples. There was some evidence of normal closure times in this study particularly at the lower doses of ASA even though TxA_2 levels suggested there was effective inhibition of COX-1. It could be that the VWF levels may have been higher in some individuals as this is an important variable for determining efficient platelet adherence to collagen and aggregation under the high shear conditions in the test. Unfortunately, VWF levels were not measured in this study but have been shown to contribute to normal closure times in other studies where poor responsiveness to ASA was observed [31].

As TxB_2 is the major metabolite of platelet derived TxA_2 in plasma/serum then this provides a direct and specific biochemical measurement of the effect of ASA on COX-1 activity. The presence of the thromboxane metabolite dTx_2 in the urine can also be directly correlated with platelet activation and inhibition of COX-1 and thromboxane generation by ASA. In this study, however dTx_2 only gave a moderate correlation with serum TxB_2 levels. As dTx_2 is being measured in urine from patients and unlike serum TxB_2 is not being generated ex vivo, this provides a global measurement of TxA_2 which could originate from other cellular sources as well as platelets [24]. Again these results are therefore unsurprising and are supported by previous studies that report discrepancies between platelet derived TxB_2 and urinary dTx_2 .

In summary in this study we have shown that not all platelet function tests used for monitoring ASA therapy in TD2 are equivalent and therefore the results are not interchangeable. As one might have predicted, platelet function tests that specifically measured COX-1 pathway (e.g. VerifyNow™-ASA, LTA-AA and Serum TxB_2) were more sensitive in detecting ASA inhibition in general, although there were clear differences in responsiveness between different doses which is probably related to T2D and not the efficacy of the COX-1 dependent tests themselves.

Although routine ASA monitoring is not currently recommended, personalising ASA therapy in high risk patients (e.g. T2D) as shown in this trial may have potential benefit providing COX-1 dependent tests were used [15]. This would certainly have to be confirmed in large prospective studies to study clinical outcomes and whether there is any increased risk in bleeding with higher dosages of ASA especially over more prolonged periods of treatment. Current guidelines also suggest that P_2Y_{12} inhibitors should also not be monitored except perhaps again in high risk individuals, so any role for personalising antiplatelet therapy with

platelet function testing is still very uncertain. Future trials should also distinguish between measuring the *in vitro* efficacy of ASA versus clinical efficacy and prevention of ischemic events. It is likely that true “ASA resistance” is rare and often caused by poor compliance but underlying platelet hyper-reactivity can often increase the risk of thrombosis despite effective COX-1 inhibition by ASA [6, 32].

Acknowledgements

The trial was sponsored by the University of Oxford and supported by a grant from the British Heart Foundation (PG/11/29/28852). It was conducted and analyzed independently by the University of Oxford Diabetes Trials Unit. Active and placebo study medication was provided by Bayer AG. The research was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre Programme. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

P.H., M.A.B. and R.R.H take responsibility for the contents of this article. P.H., M.A.B. and R.R.H. made substantial contributions to the protocol conception and design. All authors made substantial contributions to the acquisition, analysis, or interpretation of the data. P.H. drafted the manuscript and all authors revised it for intellectual content and approved the final version. R.D. performed some advice and statistical analysis and produced the final figures used in the manuscript. All authors agree to be accountable for all aspects of the work to ensure the accuracy and integrity of the data.

Declaration of Interest Statement

R.R.H. is a NIHR Senior Investigator and has received research support from Bayer, Merck, and Novartis; has attended advisory boards of Amylin, Lilly, Merck, Novartis, and Novo Nordisk; and has given lectures supported by Bayer, Lilly, Merck, and Novo Nordisk. M.A.B. receives research funding from Novartis and Bayer. P.H. is an ex-consultant for Sysmex UK and has previously received research funding from Siemens Diagnostics and Lilly when he was employed by Oxford University NHS Trust until 2012.

References

1. Natarajan A, Zaman AG, Marshall SM: Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents. *Diab Vasc Dis Res* 2008, 5(2):138-144.
2. Eskandarian R, Razavi M, Fattah A, Ghods K, Forozeshfard M: Prevalence of aspirin resistance in patients with type II diabetes: a descriptive-analytical study. *Int J Clin Pharmacol Ther* 2017, 55(6):493-497.
3. Ajjan R, Storey RF, Grant PJ: Aspirin resistance and diabetes mellitus. *Diabetologia* 2008, 51(3):385-390.
4. Weng Z, Li X, Li Y, Lin J, Peng F, Niu W: The association of four common polymorphisms from four candidate genes (COX-1, COX-2, ITGA2B, ITGA2) with aspirin insensitivity: a meta-analysis. *PLoS One* 2013, 8(11):e78093.
5. Du G, Lin Q, Wang J: A brief review on the mechanisms of aspirin resistance. *Int J Cardiol* 2016, 220:21-26.
6. Michelson AD, Cattaneo M, Eikelboom JW, Gurbel P, Kottke-Marchant K, Kunicki TJ, Pulcinelli FM, Cerletti C, Rao AK, Platelet Physiology Subcommittee of the S et al: Aspirin resistance: position paper of the Working Group on Aspirin Resistance. *J Thromb Haemost* 2005, 3(6):1309-1311.
7. Reusch JE: Diabetes, microvascular complications, and cardiovascular complications: what is it about glucose? *J Clin Invest* 2003, 112(7):986-988.
8. Alzahrani SH, Ajjan RA: Coagulation and fibrinolysis in diabetes. *Diab Vasc Dis Res* 2010, 7(4):260-273.
9. Rocca B, Santilli F, Pitocco D, Mucci L, Petrucci G, Vitacolonna E, Lattanzio S, Mattoscio D, Zaccardi F, Liani R et al: The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. *J Thromb Haemost* 2012, 10(7):1220-1230.
10. Capodanno D, Patel A, Dharmashankar K, Ferreiro JL, Ueno M, Kodali M, Tomasello SD, Capranzano P, Seecheran N, Darlington A et al: Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. *Circ Cardiovasc Interv* 2011, 4(2):180-187.
11. Spectre G, Arnetz L, Ostenson CG, Brismar K, Li N, Hjerdahl P: Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. *Thromb Haemost* 2011, 106(3):491-499.
12. Bhatt DL, Grosser T, Dong JF, Logan D, Jeske W, Angiolillo DJ, Frelinger AL, 3rd, Lei L, Liang J, Moore JE et al: Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus. *J Am Coll Cardiol* 2017, 69(6):603-612.
13. Dillinger JG, Drissa A, Sideris G, Bal dit Sollier C, Voicu S, Manzo Silberman S, Logeart D, Drouet L, Henry P: Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease. *Am Heart J* 2012, 164(4):600-606 e601.
14. Pascale S, Petrucci G, Dragani A, Habib A, Zaccardi F, Pagliaccia F, Pocaterra D, Ragazzoni E, Rolandi G, Rocca B et al: Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. *Blood* 2012, 119(15):3595-3603.
15. Bethel MA, Harrison P, Sourij H, Sun Y, Tucker L, Kennedy I, White S, Hill L, Oulhaj A, Coleman RL et al: Randomized controlled trial comparing impact on platelet reactivity

- of twice-daily with once-daily aspirin in people with Type 2 diabetes. *Diabet Med* 2016, 33(2):224-230.
16. Nielsen HL, Kristensen SD, Thygesen SS, Mortensen J, Pedersen SB, Grove EL, Hvas AM: Aspirin response evaluated by the VerifyNow Aspirin System and light transmission aggregometry. *Thromb Res* 2008, 123(2):267-273.
 17. Wang JC, Aucoin-Barry D, Manuelian D, Monbouquette R, Reisman M, Gray W, Block PC, Block EH, Ladenheim M, Simon DI: Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA. *Am J Cardiol* 2003, 92(12):1492-1494.
 18. Harrison P, Lordkipanidze M: Testing platelet function. *Hematol Oncol Clin North Am* 2013, 27(3):411-441.
 19. Hayward CP, Harrison P, Cattaneo M, Ortel TL, Rao AK, Platelet Physiology Subcommittee of the S, Standardization Committee of the International Society on T, Haemostasis: Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. *J Thromb Haemost* 2006, 4(2):312-319.
 20. Jilma-Stohlawetz P, Ratzinger F, Schorzenhofer C, Jilma B, Quehenberger P: Effect of preanalytical time-delay on platelet function as measured by multiplate, PFA-100 and VerifyNow. *Scand J Clin Lab Invest* 2016, 76(3):249-255.
 21. Lordkipanidze M, Pharand C, Schampaert E, Palisaitis DA, Diodati JG: Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease. *Int J Cardiol* 2011, 150(1):39-44.
 22. Blais N, Pharand C, Lordkipanidze M, Sia YK, Merhi Y, Diodati JG: Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B(2). *Thromb Haemost* 2009, 102(2):404-411.
 23. Harrison P, Segal H, Silver L, Syed A, Cuthbertson FC, Rothwell PM: Lack of reproducibility of assessment of aspirin responsiveness by optical aggregometry and two platelet function tests. *Platelets* 2008, 19(2):119-124.
 24. Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG: A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. *Eur Heart J* 2007, 28(14):1702-1708.
 25. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ: A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. *J Am Coll Cardiol* 2003, 41(6):961-965.
 26. Frelinger AL, 3rd, Li Y, Linden MD, Barnard MR, Fox ML, Christie DJ, Furman MI, Michelson AD: Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. *Circulation* 2009, 120(25):2586-2596.
 27. Harrison P, Segal H, Blasbery K, Furtado C, Silver L, Rothwell PM: Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry. *Stroke* 2005, 36(5):1001-1005.
 28. Consuegra-Sanchez L, Lopez-Palop R, Cano P, Carrillo P, Pico F, Villegas M, Sanchis J, Kaski JC: Assessment of high on-treatment platelet reactivity in patients with ischemic heart disease: concordance between the Multiplate and VerifyNow assays. *J Thromb Haemost* 2013, 11(2):379-381.

29. Harrison P, Robinson MS, Mackie IJ, Joseph J, McDonald SJ, Liesner R, Savidge GF, Pasi J, Machin SJ: Performance of the platelet function analyser PFA-100 in testing abnormalities of primary haemostasis. *Blood Coagul Fibrinolysis* 1999, 10(1):25-31.
30. McCabe DJ, Murphy SJ, Starke R, Harrison P, Brown MM, Sidhu PS, Mackie IJ, Scully M, Machin SJ: Relationship between ADAMTS13 activity, von Willebrand factor antigen levels and platelet function in the early and late phases after TIA or ischaemic stroke. *J Neurol Sci* 2015, 348(1-2):35-40.
31. Diciara J, Bliden KP, Tantry US, Chaganti SK, Kreutz RP, Gesheff TB, Kreutz Y, Gurbel PA: Platelet function measured by VerifyNow identifies generalized high platelet reactivity in aspirin treated patients. *Platelets* 2007, 18(6):414-423.
32. Cattaneo M: Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection. *J Thromb Haemost* 2007, 5 Suppl 1:230-237.

Figure Legends

Figure 1. Distribution of COX-1 dependent platelet function test results by each test for baseline (blue) and each ASA dose (100 mg (green), 200 mg (black) and 100 mg x 2 (red)). A – VerifyNow™-ASA (ARU), B – LTA (AA) (%), C – WBA (AA) (AUC), D – Serum TxB₂ (ng/ml) and E – Urinary dTxB₂ (pg/ml). Platelet reactivity was significantly decreased ($P < 0.0001$) in all tests at each ASA dose compared to baseline. Any significant differences between ASA dosages in each test are shown.

Figure 2. Distribution of non-COX-1 dependent platelet function test results by each test for baseline (blue) and each ASA dose (100 mg (green), 200 mg (black) and 100 mg x 2 (red)). A – PFA-100™CEPI (seconds), B – PFA-100™-CADP (seconds), C – LTA (ADP) and D – WBA (ADP) (AUC). Dotted lines denote the cut-off values for each test. Platelet reactivity was significant decreased ($P < 0.0001$) in the PFA-100™CEPI and LTA (ADP) tests at each ASA dose compared to baseline but not in the PFA-100™-CADP and WBA (ADP) tests. Any significant differences between ASA dosages in each test are shown.

Figure 3. Scatterplots comparing all platelet function tests with serum TxB₂ levels (ng/ml). Baseline values are shown as blue dots, 100 mg ASA as green squares, 200 mg ASA as black triangles and 100 mg x 2 ASA as red squares. A – VerifyNow™-ASA (ARU), B – LTA (AA) (%), C – WBA (AA) (AUC), D – Urinary dTxB₂ (pg/ml), E – PFA-100™-CEPI (seconds), F – LTA (ADP), G – PFA-100™CADP (seconds) and H – WBA (ADP) (AUC). The solid lines denote the cut-off values for each test.

Figure 4. Scatterplots comparing all platelet function tests with LTA-AA (%). Baseline values are shown as blue dots, 100 mg ASA as green squares, 200 mg ASA as black triangles and 100 mg x 2 ASA as red squares. A – VerifyNow™-ASA (ARU), B – LTA (AA) (%), C – Serum TxB₂ (ng/ml), D – Urinary dTxB₂ (pg/ml), E – PFA-100™CEPI (seconds), F – LTA (ADP), G – PFA-100™CADP (seconds) and H – WBA (ADP) (AUC). The solid lines denote the cut-off values for each test.

Table 1. Overall kappa statistic classifications for each platelet function test at baseline with either all or each individual ASA dosage regime.

Values 0–0.20 are classified as poor, 0.21–0.40 fair, 0.41–0.60 as moderate, 0.61–0.80 as good, and 0.81–1 as very good.

ASA Dose	VerifyNow™- ASA	LTA- AA	WBA- AA	LTA- ADP	WBA- ADP	PFA-100™ CEPI	PFA-100™ CADP	Serum TxB₂	Urine TxB₂
all	0.85	0.95	0.47	0.59	-0.07	0.56	-0.02	0.79	0.55
100 mg OD	0.91	0.96	0.41	0.49	-0.10	0.57	-0.08	0.74	0.62
200 mg OD	0.92	0.96	0.42	0.46	0.04	0.67	0.00	0.88	0.63
100 mg BD	0.96	1.00	0.42	0.46	0.25	0.79	0.04	0.96	0.67